Is Amgen Stock Undervalued Stock Or Value Trap?
Amgen (AMGN) stock is at an interesting point right now. It is trading cheap, and if you bet on it, you are betting on a company that’s growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capitalization structure, and is relatively cheaply valued. But is that enough?
Why Bet On AMGN Now?
The investment thesis is centered on the ability of the high-growth portfolio (Rare Disease, Repatha, EVENITY, TEZSPIRE) and the successful advancement of the MariTide obesity drug to generate enough new revenue to more than offset the predictable, but significant, sales erosion from the Prolia/Xgeva loss of exclusivity.
- The acquired Rare Disease portfolio grew 14% year-over-year to $5.2B.
- Key growth drivers demonstrated strong FY2025 performance: Repatha grew 36%, EVENITY grew 34%, and TEZSPIRE grew 52%.
- The obesity drug candidate, MariTide, is advancing through a large Phase 3 program, targeting a potential $100 billion market by 2030.
How Do The Fundamentals Look?
- Revenue Growth: 10.0% LTM and 11.9% last 3 year average.
- Operating Margin: Nearly 24.8% 3-year average operating margin.
- No Margin Shock: Amgen has improved in the last 12 months.
- Modest Valuation: Despite these fundamentals, AMGN stock trades at a PE multiple of 23.6
Below is a quick comparison of AMGN fundamentals with S&P medians.
| AMGN | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Biotechnology | – |
| PE Ratio | 23.6 | 23.9 |
|
|
||
| LTM* Revenue Growth | 10.0% | 6.8% |
| 3Y Average Annual Revenue Growth | 11.9% | 5.5% |
| LTM Operating Margin Change | 3.0% | 0.2% |
|
|
||
| LTM* Operating Margin | 24.7% | 18.6% |
| 3Y Average Operating Margin | 24.8% | 18.2% |
| LTM* Free Cash Flow Margin | 22.0% | 14.2% |
*LTM: Last Twelve Months
The Bear View & The Current Investment Debate
The current investment debate on AMGN is centered around: The conflict between strong growth from new products (Rare Disease, Repatha, TEZSPIRE) and the certain, significant revenue loss from the Prolia/Xgeva franchise facing biosimilar competition.
The prevailing sentiment is bearish. A formidable set of anticipated headwinds. The anticipated loss of exclusivity for Prolia/Xgeva, and IRA pricing pressure, create a significant revenue hole. Weakening FCF conversion and opex bloat suggest execution challenges.
| Bull View | Bear View |
|---|---|
| The growth portfolio and MariTide obesity pipeline will generate enough new revenue to more than offset the predictable Prolia/Xgeva sales erosion, enabling a return to sustainable growth. | The Prolia/Xgeva sales decline will be faster and deeper than expected, creating a revenue gap that the current growth drivers cannot fill, leading to near-term earnings misses. |
You can evaluate more on which view to bet on by visiting AMGN Investment Highlights & Full Analysis
AMGN Is Just One of Several Such Stocks
Not ready to act on AMGN? Consider these alternatives:
These stocks have strong operating margin, and are trading meaningfully below 1Y high with P/E below S&P 500 median and P/S below historical average.
A portfolio that was built starting 12/31/2016 with stocks that fulfill the criteria above would have resulted in average 6-month and 12-month forward returns of 12.7% and 25.8% respectively, with win rate (percentage of picks returning positive) of above 70%.
The Right Way To Invest Is Through Portfolios
Individual stocks can soar or tank, but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside, and mitigate the downside associated with any individual stock.
Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.